Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

statuteappealpatenttrademarkstatute of limitations
statuteappealpatenttrademarkstatute of limitations

Related Cases

Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, 584 U.S. 325, 138 S.Ct. 1365, 200 L.Ed.2d 671, 86 USLW 4242, 126 U.S.P.Q.2d 1293, 18 Cal. Daily Op. Serv. 3723, 2018 Daily Journal D.A.R. 3609, 27 Fla. L. Weekly Fed. S 197
View Case »
Gillman v. Stern, 114 F.2d 28, 46 U.S.P.Q. 430
View Case »
Poly-America, L.P. v. API Industries, Inc., 666 F.Supp.3d 415
View Case »
Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93, 136 S.Ct. 1923, 195 L.Ed.2d 278, 84 USLW 4386, 118 U.S.P.Q.2d 1761, 16 Cal. Daily Op. Serv. 6086, 2016 Daily Journal D.A.R. 5663, 26 Fla. L. Weekly Fed. S 246
View Case »
Process Control Corp. v. HydReclaim Corp., 190 F.3d 1350, 52 U.S.P.Q.2d 1029
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Novartis AG v. Lee, 740 F.3d 593, 109 U.S.P.Q.2d 1385

Facts

Novartis AG and its affiliates challenged the Patent and Trademark Office's (PTO) determinations regarding patent term adjustments (PTAs) for 23 patents. The district court dismissed claims for 19 patents as untimely but granted relief for the remaining claims. Novartis appealed the dismissal, while the PTO director filed a cross-appeal regarding the court's interpretation of the relevant statutes governing PTAs. The case primarily revolved around the application of a 180-day statute of limitations for challenging PTA determinations.

Novartis AG and its affiliates challenged the Patent and Trademark Office's (PTO) determinations regarding patent term adjustments (PTAs) for 23 patents. The district court dismissed claims for 19 patents as untimely but granted relief for the remaining claims. Novartis appealed the dismissal, while the PTO director filed a cross-appeal regarding the court's interpretation of the relevant statutes governing PTAs. The case primarily revolved around the application of a 180-day statute of limitations for challenging PTA determinations.

Issue

Whether the 180-day statute of limitations for challenging patent term adjustment determinations applies to final adjustments announced at issuance and whether Novartis was entitled to equitable tolling of this statute.

Whether the 180-day statute of limitations for challenging patent term adjustment determinations applies to final adjustments announced at issuance and whether Novartis was entitled to equitable tolling of this statute.

Rule

Analysis

The court found that the 180-day statute of limitations applies to all patent term adjustment determinations, including final adjustments. Novartis's argument that it could wait for another patentee to establish a legal standard did not meet the criteria for equitable tolling, as it failed to show extraordinary circumstances that prevented timely filing. The court affirmed the district court's dismissal of claims for 15 patents as untimely and partly reversed the judgment regarding the remaining patents, agreeing with Novartis on the interpretation of the statute concerning continued examinations.

The court found that the 180-day statute of limitations applies to all patent term adjustment determinations, including final adjustments. Novartis's argument that it could wait for another patentee to establish a legal standard did not meet the criteria for equitable tolling, as it failed to show extraordinary circumstances that prevented timely filing. The court affirmed the district court's dismissal of claims for 15 patents as untimely and partly reversed the judgment regarding the remaining patents, agreeing with Novartis on the interpretation of the statute concerning continued examinations.

Conclusion

The court affirmed in part and reversed in part the district court's ruling, ultimately remanding the case for redetermination of the proper patent term adjustments for three patents.

The court affirmed in part and reversed in part the district court's ruling, ultimately remanding the case for redetermination of the proper patent term adjustments for three patents.

Who won?

The prevailing party in this case was the Patent and Trademark Office (PTO) regarding the dismissal of claims for 15 patents, as the court upheld the district court's interpretation of the statute of limitations. However, Novartis prevailed on the interpretation of the statute concerning the calculation of patent term adjustments for the remaining three patents, leading to a partial reversal of the district court's decision.

The prevailing party in this case was the Patent and Trademark Office (PTO) regarding the dismissal of claims for 15 patents, as the court upheld the district court's interpretation of the statute of limitations. However, Novartis prevailed on the interpretation of the statute concerning the calculation of patent term adjustments for the remaining three patents, leading to a partial reversal of the district court's decision.

You must be